CASI Pharmaceuticals (CASI) to Release Earnings on Wednesday

CASI Pharmaceuticals (NASDAQ:CASI) is expected to be posting its resultson Wednesday, April 29th. Analysts expect CASI Pharmaceuticals to post earnings of ($0.36) per share for the quarter.

CASI Pharmaceuticals Stock Performance

NASDAQ CASI opened at $0.21 on Monday. The company has a market capitalization of $2.55 million, a price-to-earnings ratio of -0.07 and a beta of 0.91. The company’s 50-day simple moving average is $0.29 and its two-hundred day simple moving average is $0.83. CASI Pharmaceuticals has a one year low of $0.21 and a one year high of $3.09.

Institutional Trading of CASI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP bought a new stake in shares of CASI Pharmaceuticals in the 3rd quarter valued at about $55,000. Woodline Partners LP boosted its holdings in shares of CASI Pharmaceuticals by 64.9% in the 1st quarter. Woodline Partners LP now owns 164,365 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 64,675 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of CASI Pharmaceuticals by 2,013.3% in the 3rd quarter. Bank of America Corp DE now owns 254,884 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 242,823 shares in the last quarter. 22.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CASI Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.00.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers.